Bengaluru, India, January 24, 2017/Team Estrade//– Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, announced today its consolidated financial results for the third quarter ended on December 31, 2016.
Commenting on the quarterly performance and highlights, Chairperson and Managing Director, Kiran Mazumdar-Shaw stated:
“Our strong performance in Q3FY17 was led by robust growth of our Biologics business with both insulins and biosimilar MAbs gaining traction in Japan and key emerging markets. The commercialization of our Malaysian facility was a key milestone this quarter. Other major milestones this quarter were the acceptance of our first Biologics License Application (BLA) for the proposed biosimilar Trastuzumab by US FDA, and Marketing Authorization Application (MAA) for Insulin Glargine by EMA. These developments have strengthened Biocon’s position as a front runner in the arena of biosimilars. Our Small Molecules and Research Services businesses also reported strong growth this quarter.”
Highlights: Q3FY17
- Biologics License Application (BLA) for a proposed biosimilar Trastuzumab accepted for review by the US FDA; Marks first US regulatory submission through the Mylan/Biocon collaboration.
- Marketing Authorization Application (MAA) for Insulin Glargine co-developed by Biocon and Mylan accepted for review by European Medicines Agency (EMA)
- The prestigious Journal of the American Medical Association (JAMA) published the clinical study results of biosimilar Trastuzumab after a rigorous peer review process.
- Biocon’s Insulins facility in Malaysia commenced commercial operations with ‘Made in Malaysia’ product introduced in Malaysia.
- A three year contract for supplying rh-Insulin cartridges and re-usable insulin pens awarded to Biocon SDN. BHD. by Ministry of Health (MoH) Malaysia.
- Biocon ranked among the world’s Top Ten Best Employers in Biotechnology by Science magazine; The only Asian company to feature in 2016 list.
- Biocon’s novel diabetes education initiative for medical practitioners, ABIDE, conferred with the ‘Award of Recognition’ by the prestigious Research Society for the Study of Diabetes in India.
- Biocon debuts on the prestigious Asia IP Elite 2016 list; Only pharmaceutical company from India to be recognized for IP-led value creation by IP Business Congress Asia.
Financial Highlights: Q3 FY17
| As per IND-AS (In Rs crore, except growth numbers) |
| Particulars | Q3 FY17 | Q3 FY16 | Growth (%) |
| INCOME | |||
| Small Molecules | 390 | 315 | 24 |
| Biologics | 120 | 75 | 61 |
| Branded Formulations | 123 | 104 | 18 |
| Licensing | 79 | 32 | 148 |
| Syngene: Research Services | 317 | 270 | 17 |
| Total Sales | 1029 | 796 | 29 |
| Other Income | 63 | 33 | 88 |
| TOTAL REVENUE | 1092 | 829 | 32 |
| EBITDA | 324 | 206 | 57 |
| Net Profit | 171 | 104 | 65 |
| R&D Expenses in P&L |
85 | 68 | 25 |
| Gross R&D Spends | 100 | 91 | 10 |
| EBITDA Margin | 30% | 25% | – |
| Net Profit Margin | 16% | 13% | – |
| Note: The figures above are rounded off to the nearest Cr; % based on absolute nos. For financials in IGAAP kindly refer to the fact sheet |
EXECUTIVE COMMENTARY
PERFORMANCE OVERVIEW
Biocon reported a revenue growth of 32% at Rs 1092 Cr in Q3FY17, which was led by a robust growth of 61% in the Biologics business, 24% growth recorded by Small Molecules, 18% by Branded Formulations and 17 % growth by Research Services businesses. Licensing Income stood at Rs 79 Cr and Other Income was Rs 63 Cr.
EBITDA rose 57% to Rs 324 Cr; Net Profit stood at Rs 171 Cr a growth of 65% over last year.
Net R&D spends during the quarter stood at Rs. 85 Cr, an increase of 25% YoY. At a Gross level, R&D spends in Q3FY17 were Rs 100 Cr largely on account of the clinical advancement of several of our programs.
Q3FY17 also saw a strong contribution from our international business wherein we supply both Active Pharmaceutical Ingredients (APIs) and formulations across our Small Molecules and Biosimilars segments.
SMALL MOLECULES
The Small Molecules business reported strong revenue growth of 24% to Rs 390 Cr, led by good traction in its business in India, Europe, LatAm and NAFTA for statins, immunosuppressants and specialty products. A strong demand for Rosuvastatin API post genericization in the US market as well as the acquisition of new customers for statins and immunosuppressant APIs provided a fillip to the business.
Biocon received Final Approval from the US FDA for generic Rosuvastatin Calcium tablets, the first such approval for our Generic Formulations business in the US.
BIOLOGICS
The Biologics segment comprising Novels and Biosimilars, including rh-insulin, insulin analogs, monoclonal antibodies and recombinant proteins, reported a strong growth of 61% at Rs 120 Cr. Biocon with its global partner Mylan made good regulatory progress in its biosimilar and insulin analogs global development programs.
Biosimilars
Insulins & Analogs
Our Insulins business recorded a strong growth this quarter led by the expansion of our commercial footprint and increased traction in some of the key emerging markets.
Biocon commenced commercial operations from its Malaysian manufacturing facility with the launch of its rh-Insulin in Malaysia. The Company has been awarded a three-year contract by Ministry of Health (MoH) for supplying rh-Insulin cartridges and re-usable insulin pens for people with diabetes in Malaysia. The contract is extendable for additional two years, subject to government’s approval.
Biocon’s ready-to-use, prefilled disposable Insulin Glargine pen, launched in Japan in Q2FY17 continues to do well with increase in market share. The product has been introduced in a few more emerging markets this quarter.
During the quarter, the Marketing Authorization Application (MAA) for Insulin Glargine, co-developed by Biocon and Mylan was accepted for review by the European Medicines Agency (EMA). It is a significant development considering it is the first filing in a developed market incorporating a product validated at our state-of-the-art Malaysia facility.
Several other regulatory filings and audits are underway to enable commercial sales from the new Malaysian manufacturing facility.
Monoclonal Antibodies & Recombinant Proteins
The Biocon-Mylan collaboration to co-develop a broad portfolio of biosimilar products for the global marketplace made good progress and achieved critical milestones in US and Europe in Q3FY17.
The most significant development was the acceptance for review of our Biologics License Application (BLA) for a proposed biosimilar Trastuzumab by the US FDA. This is Mylan and Biocon’s first U.S. regulatory submission through the 351(k) pathway and the acceptance of the BLA positions the two companies among the first to be able to address the critical need of US patients for a high-quality biosimilar to treat certain HER2-positive breast cancers.
Earlier in the quarter, the Journal of the American Medical Association (JAMA) had published data from Biocon and Mylan’s safety and efficacy study that demonstrated equivalent overall response rate for their proposed biosimilar Trastuzumab in comparison to branded Trastuzumab. The results indicate that a biosimilar can deliver similar safety, efficacy and immunogenicity in comparison to a branded product.
Biocon also entered into a strategic agreement for Trastuzumab in one of the leading emerging markets.
Novel Biologics
Our Novel programs, Itolizumab (anti-CD6 monoclonal antibody) and QPI 1007 (SiRNA), are progressing actively in the ongoing clinical trials. The clinical study using a sub-cutaneous form of Itolizumab, currently on in Australia has completed stage-1 dose escalation and stage-2 is being initiated. No severe adverse safety events have been reported. QPI 1007, undergoing a global phase III trial in NIAON patients, a rare ophthalmic disease, is recruiting actively in several regions including India.
We have finalized the clinical plan to progress Insulin Tregopil and will file a Clinical Trial Application (CTA) with the Indian regulator to clinically validate its promise as an orally delivered, rapid acting prandial insulin.
New preclinical data on the novel immunotherapy product, Fmab2, was presented at the Society for Immunotherapy meeting in Washington DC, recently.
BRANDED FORMULATIONS
The Branded Formulations business which includes sales in India and UAE reported sales of Rs 123 Cr during Q3FY17. The business was impacted by the discontinuance of in-licensed Abraxane®.
The Branded Formulations India business focuses on critical therapies and specialty brands. 16 of our brands are category leaders and feature amongst the Top three.
CANMAb™ our Trastuzumab brand continues to gain traction and features in the Top 10 Oncology brands in India with a market share of 22% (MAT-IPSoS).
Our novel diabetes education initiative for medical practitioners, ABIDE, was conferred with the ‘Award of Recognition’ by the prestigious Research Society for the Study of Diabetes in India.
Our key brands in UAE continue to gain traction with overall prescription share of the Company recording a 60% growth as per IMS (Apr-Sep 2016).
RESEARCH SERVICES – SYNGENE
Our Research Services business through Syngene reported revenue growth of 17% to Rs 317 Cr, which was driven by broad-based growth across the Dedicated R&D Centers and Discovery Services verticals.
During the quarter, there was an unfortunate fire at one of the blocks of Syngene that housed some biologics and analytical laboratories. There were no injuries or loss of life due to the fire. Following the incident, Syngene implemented its business continuity plan and all ongoing projects of that block along with the scientific teams were relocated to other parts of the facility to minimize impact on the client projects. The Company’s ‘Industrial All Risk’ policy will help in minimizing financial impact of the incident.
NEW APPOINTMENT
The Board of Directors of the Company have approved the appointment of Rajiv Balakrishnan as the Company Secretary for Biocon Limited. Rajiv is a Fellow Company Secretary from Institute of Company Secretaries of India and brings with him over 15 years of diverse experience across Secretarial, Legal, Investor Relations and Finance functions. Prior to joining Biocon, he was working as Company Secretary & Additional General Manager – Investor Relations with VA Tech Wabag Limited.
Enclosed: Fact Sheet – with Financials as per IND-AS and IGAAP
BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET
|
(Rs Cr) |
|||||
|
December 31, 2016 |
March 31, 2016 |
||||
| ASSETS | |||||
| Non-current assets | |||||
| (a) Property, plant and equipment |
1,763 |
1,681 |
|||
| (b) Capital work-in-progress |
2,330 |
2,062 |
|||
| (c) Investment property |
1 |
1 |
|||
| (d) Goodwill |
26 |
26 |
|||
| (e) Other intangible assets |
46 |
41 |
|||
| (f) Intangible assets under development |
296 |
180 |
|||
| (g) Investments in associates and a joint venture |
43 |
32 |
|||
| (h) Financial assets | |||||
| Loans and advances |
30 |
31 |
|||
| Other financial assets |
111 |
114 |
|||
| (i) Income tax asset, net |
91 |
91 |
|||
| (j) Deferred tax asset, net |
70 |
74 |
|||
| (k) Other non-current assets |
240 |
234 |
|||
|
5,047 |
4,567 |
||||
| Current assets | |||||
| (a) Inventories |
604 |
542 |
|||
| (b) Financial assets | |||||
| Investments |
441 |
432 |
|||
| Trade receivables |
907 |
712 |
|||
| Cash and cash equivalents |
551 |
1,123 |
|||
| Other bank balances |
1,260 |
805 |
|||
| Other financial assets |
238 |
233 |
|||
| (c) Other current assets |
167 |
65 |
|||
|
4,168 |
3,912 |
||||
| TOTAL |
9,215 |
8,479 |
|||
| EQUITY AND LIABILITIES | |||||
| Equity | |||||
| (a) Share capital |
100 |
100 |
|||
| (b) Other equity |
4,528 |
3,958 |
|||
| Equity attributable to equity holders of the Company |
4,628 |
4,058 |
|||
| Non-controlling interest |
352 |
286 |
|||
|
4,980 |
4,344 |
||||
| Non-current liabilities | |||||
| (a) Financial liabilities | |||||
| Borrowings |
2,230 |
2,072 |
|||
| Other financial liabilities |
8 |
19 |
|||
| (b) Provisions |
35 |
30 |
|||
| (c) Other non-current liabilities |
364 |
371 |
|||
|
2,637 |
2,492 |
||||
| Current liabilities | |||||
| (a) Financial liabilities | |||||
| Borrowings |
315 |
395 |
|||
| Trade payables |
695 |
524 |
|||
| Other financial liabilities |
327 |
296 |
|||
| (b) Short-term provision |
46 |
37 |
|||
| (c) Income tax liability, net |
113 |
75 |
|||
| (d) Other current liabilities |
102 |
316 |
|||
|
1,598 |
1,643 |
||||
| TOTAL |
9,215 |
8,479 |
| BIOCON LIMITED (CONSOLIDATED) | ||||||||
| PROFIT & LOSS STATEMENT |
(Rs. Cr) |
|||||||
|
9M – FY17 |
9M – FY16 | Variance |
Variance |
|||||
| Particulars |
IGAAP |
Adj | IndAS | IGAAP | Adj | IndAS | IGAAP |
IndAS |
| INCOME | ||||||||
| Biocon |
1,982 |
102 | 2,084 | 1,737 | (89) | 1,648 | 14% |
27% |
| Small molecules |
1,121 |
78 | 1,199 | 977 | 15 | 992 | 15% |
21% |
| Biologics |
322 |
16 | 338 | 237 | (15) | 222 | 36% |
52% |
| Branded formulations |
419 |
(1) | 418 | 425 | (89) | 336 | -2% |
24% |
| Licensing# |
120 |
9 | 129 | 98 | – | 98 | 24% |
33% |
| Syngene – Research Services |
866 |
– | 866 | 744 | – | 744 | 16% |
16% |
| Total Sales |
2,848 |
102 | 2,950 | 2,481 | (89) | 2,392 | 15% |
23% |
| Other income |
158 |
9 | 167 | 87 | 8 | 95 | 80% |
74% |
| TOTAL REVENUE |
3,006 |
111 | 3,117 | 2,568 | (81) | 2,487 | 17% |
25% |
| EXPENDITURE | ||||||||
| Material & Power costs |
1,183 |
45 | 1,228 | 1,085 | (11) | 1,074 | 9% |
14% |
| Staff costs |
504 |
5 | 509 | 424 | (19) | 405 | 19% |
26% |
| Research & Development expenses* |
201 |
– | 201 | 175 | (1) | 174 | 15% |
15% |
| Other expenses |
263 |
10 | 273 | 217 | (10) | 207 | 21% |
31% |
| Manufacturing, staff & other expenses |
2,151 |
60 | 2,211 | 1,901 | (41) | 1,860 | 13% |
19% |
| EBITDA |
855 |
51 | 906 | 667 | (40) | 627 | 28% |
45% |
| Interest & Finance charges |
21 |
– | 21 | 9 | – | 9 | 139% |
139% |
| Depreciation & Amortisation |
199 |
6 | 205 | 180 | 4 | 184 | 11% |
11% |
| Share of profit in JV |
(11) |
– | (11) | – | (16) | (16) | – |
-34% |
| PBT BEFORE EXCEPTIONAL ITEM |
646 |
45 | 691 | 478 | (28) | 450 | 35% |
54% |
| Exceptional item, Net |
– |
– | – | 307 | (415) | (108) | – |
– |
| PBT |
646 |
45 | 691 | 785 | (443) | 342 | -18% |
102% |
| Taxes |
135 |
16 | 151 | 95 | (7) | 88 | 43% |
73% |
| Taxes on exceptional item |
– |
– | – | 104 | (104) | – | – |
– |
| NET PROFIT BEFORE MINORITY INTEREST |
511 |
29 | 540 | 586 | (332) | 254 | -13% |
112% |
| Minority interest |
54 |
1 | 55 | 51 | (14) | 37 | 5% |
48% |
| NET PROFIT FOR THE PERIOD |
457 |
28 | 485 | 535 | (318) | 217 | -15% |
123% |
| EPS Rs. |
22.9 |
24.3 | 26.8 | 10.9 | ||||
| NET PROFIT BEFORE EXCEPTIONAL ITEM |
457 |
28 | 485 | 332 | (7) | 325 | 38% |
49% |
| Exceptional item, net of taxes |
– |
– | – | 203 | (311) | (108) | ||
| NET PROFIT FOR THE PERIOD |
457 |
28 | 485 | 535 | (318) | 217 | -15% |
123% |
| Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers | ||||||||
| # Including one time compensation from customer during Q1 – FY16 | ||||||||
| * Gross Research & Development expenses |
304 |
275 | ||||||
| BIOCON LIMITED (CONSOLIDATED) | ||||||||
| PROFIT & LOSS STATEMENT |
(Rs. Cr) |
|||||||
|
Q3 – FY17 |
Q3 – FY16 | Variance |
Variance |
|||||
| Particulars |
IGAAP |
Adj | IndAS | IGAAP | Adj | IndAS | IGAAP |
IndAS |
| INCOME | ||||||||
| Biocon |
705 |
7 | 712 | 558 | (32) | 526 | 26% |
35% |
| Small molecules |
383 |
7 | 390 | 318 | (3) | 315 | 20% |
24% |
| Biologics |
120 |
– | 120 | 80 | (5) | 75 | 51% |
61% |
| Branded formulations |
123 |
– | 123 | 128 | (24) | 104 | -4% |
18% |
| Licensing# |
79 |
– | 79 | 32 | – | 32 | 147% |
148% |
| Syngene – Research Services |
317 |
– | 317 | 270 | – | 270 | 17% |
17% |
| Total Sales |
1,022 |
7 | 1,029 | 828 | (32) | 796 | 23% |
29% |
| Other income |
59 |
4 | 63 | 25 | 8 | 33 | 136% |
88% |
| TOTAL REVENUE |
1,081 |
11 | 1,092 | 853 | (24) | 829 | 27% |
32% |
| EXPENDITURE | ||||||||
| Material & Power costs |
407 |
– | 407 | 354 | (10) | 344 | 15% |
18% |
| Staff costs |
177 |
2 | 179 | 146 | (7) | 139 | 21% |
29% |
| Research & Development expenses* |
85 |
– | 85 | 68 | – | 68 | 25% |
25% |
| Other expenses |
90 |
7 | 97 | 76 | (4) | 72 | 17% |
34% |
| Manufacturing, staff & other expenses |
759 |
9 | 768 | 644 | (21) | 623 | 18% |
23% |
| EBITDA |
322 |
2 | 324 | 209 | (3) | 206 | 54% |
57% |
| Interest & Finance charges |
9 |
– | 9 | 2 | – | 2 | 487% |
487% |
| Depreciation & Amortisation |
69 |
2 | 71 | 62 | 2 | 64 | 10% |
10% |
| Share of profit in JV |
(1) |
– | (1) | – | (3) | (3) | – |
-69% |
| PBT BEFORE EXCEPTIONAL ITEM |
245 |
– | 245 | 145 | (2) | 143 | 69% |
71% |
| Exceptional item, Net |
– |
– | – | – | – | – | – |
– |
| PBT |
245 |
– | 245 | 145 | (2) | 143 | 69% |
71% |
| Taxes |
54 |
1 | 55 | 24 | (2) | 22 | 122% |
150% |
| Taxes on exceptional item |
– |
– | – | – | – | – | – |
– |
| NET PROFIT BEFORE MINORITY INTEREST |
191 |
(1) | 190 | 121 | – | 121 | 58% |
57% |
| Minority interest |
19 |
– | 19 | 18 | (1) | 17 | 8% |
10% |
| NET PROFIT FOR THE PERIOD |
172 |
(1) | 171 | 103 | 1 | 104 | 67% |
65% |
| EPS Rs. |
8.6 |
8.6 | 5.2 | 5.2 | ||||
| Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers | ||||||||
| * Gross Research & Development expenses |
100 |
91 |
||||||
| BIOCON LIMITED (CONSOLIDATED) | |||||||||
| PROFIT & LOSS STATEMENT |
(Rs. Cr) |
||||||||
| Q3 – FY17 | Q2 – FY17 | Variance |
Variance |
||||||
| Particulars |
IGAAP |
Adj | IndAS | IGAAP | Adj | IndAS | IGAAP |
IndAS |
|
| INCOME | |||||||||
| Biocon |
705 |
7 | 712 | 637 | 17 | 654 | 11% |
9% |
|
| Small molecules |
383 |
7 | 390 | 380 | 9 | 389 | 1% |
0% |
|
| Biologics |
120 |
– | 120 | 96 | – | 96 | 24% |
24% |
|
| Branded formulations |
123 |
– | 123 | 137 | (1) | 136 | -10% |
-10% |
|
| Licensing |
79 |
– | 79 | 24 | 9 | 33 | 225% |
142% |
|
| Syngene – Research Services |
317 |
– | 317 | 286 | – | 286 | 11% |
11% |
|
| Total Sales |
1,022 |
7 | 1,029 | 923 | 17 | 940 | 11% |
9% |
|
| Other income |
59 |
4 | 63 | 50 | 3 | 53 | 19% |
20% |
|
| TOTAL REVENUE |
1,081 |
11 | 1,092 | 973 | 20 | 993 | 11% |
10% |
|
| EXPENDITURE | |||||||||
| Material & Power costs |
407 |
– | 407 | 382 | 1 | 383 | 6% |
6% |
|
| Staff costs |
177 |
2 | 179 | 164 | 2 | 166 | 8% |
8% |
|
| Research & Development expenses* |
85 |
– | 85 | 65 | – | 65 | 30% |
30% |
|
| Other expenses |
90 |
7 | 97 | 99 | 2 | 101 | -9% |
-4% |
|
| Manufacturing, staff & other expenses |
759 |
9 | 768 | 710 | 5 | 715 | 7% |
8% |
|
| EBITDA |
322 |
2 | 324 | 263 | 15 | 278 | 23% |
16% |
|
| Interest & Finance charges |
9 |
– | 9 | 7 | – | 7 | 35% |
35% |
|
| Depreciation & Amortisation |
69 |
2 | 71 | 66 | 2 | 68 | 3% |
3% |
|
| Share of profit in JV |
(1) |
– | (1) | (5) | – | (5) | – |
-83% |
|
| PBT BEFORE EXCEPTIONAL ITEM |
245 |
– | 245 | 195 | 13 | 208 | 26% |
18% |
|
| Exceptional item, Net |
– |
– | – | – | – | – | – |
– |
|
| PBT |
245 |
– | 245 | 195 | 13 | 208 | 26% |
18% |
|
| Taxes |
54 |
1 | 55 | 39 | 2 | 41 | 38% |
30% |
|
| Taxes on exceptional item |
– |
– | – | – | – | – | – |
– |
|
| NET PROFIT BEFORE MINORITY INTEREST |
191 |
(1) | 190 | 156 | 11 | 167 | 23% |
15% |
|
| Minority interest |
19 |
– | 19 | 18 | 1 | 19 | 6% |
-2% |
|
| NET PROFIT FOR THE PERIOD |
172 |
(1) | 171 | 138 | 10 | 148 | 26% |
17% |
|
| EPS Rs. |
8.6 |
8.6 | 6.9 | 7.4 | |||||
| Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers | |||||||||
| * Gross Research & Development expenses | 100 | 113 | |||||||
About Biocon Limited
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India’s largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 100 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from ‘Lab to Market’. Some of its key brands are INSUGEN®(rh-insulin), BASALOG®(Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™(Nimotuzumab) and ALZUMAb™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin analog. Visit: www.biocon.com
Earnings Call
The company will conduct a call at 9.00 AM IST on January 25, 2017 where the senior management will discuss the company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is +91-22-3938 1081. Other toll numbers are listed in the conference call invite which is posted on the company website www.biocon.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available from the conclusion of the call till January 29, 2017 on +91 22 3065 2322/6181 3322 , Playback ID: 44711. Transcript of the conference call will be uploaded on the company website in due course.
Disclaimer:
Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our affiliates, have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.
SOURCE: http://www.biocon.com/
Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore
